Kiniksa Pharmaceuticals International, plc
KNSA
$20.21
-$0.325-1.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 29.98% | -224.80% | 77.93% | -170.15% | 282.15% |
| Total Depreciation and Amortization | 0.25% | -7.21% | -7.73% | -13.70% | -10.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 50.90% | -76.00% | 46.72% | 172.31% | -190.99% |
| Change in Net Operating Assets | 266.47% | 156.55% | -215.53% | 316.56% | -135.96% |
| Cash from Operations | 939.45% | -143.27% | 29.62% | -7.82% | -74.54% |
| Capital Expenditure | -- | -- | 100.00% | -50.00% | -250.00% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,131.60% | 86.44% | -282.84% | 272.58% | -21.02% |
| Cash from Investing | 1,128.56% | 86.44% | -283.35% | 271.37% | -21.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -71.07% | 728.28% | -71.58% | 317.35% | -42.25% |
| Repurchase of Common Stock | 78.69% | -106.55% | -244.62% | -45.42% | 76.29% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -67.98% | 3,857.87% | -104.93% | 419.86% | 25.91% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,649.08% | 95.47% | -226.21% | 435.47% | -287.68% |